Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 15Phase 1/2 4Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 28Breast Neoplasms 23Neoplasms 21Pancreatic Neoplasms 17Prostatic Neoplasms 16Glioma 16Glioblastoma 16Recurrence 14Leukemia, Myeloid, Acute 14Solid Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Hematologic Neoplasms 8Melanoma 7Lymphoma, B-Cell 7Lymphoma 7Colorectal Neoplasms 7Polycystic Ovary Syndrome 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Advanced Solid Tumors 6Myelodysplastic Syndromes 5Leukemia, Plasma Cell 5Leukemia 5

Interventions

daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT06398457 2025-09-26

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
8 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡